Design Therapeutics (DSGN) Prepaid Assets (2020 - 2026)
Design Therapeutics (DSGN) posted quarterly Prepaid Assets of $4.6 million for Q2 2026, up 31.24% year-over-year from $3.5 million in Q2 2025, and up 9.25% on a QoQ basis from $4.2 million in Q1 2026.
Design Therapeutics (DSGN) Prepaid Assets (2020 - 2026) Analysis & Trends
Design Therapeutics has reported Prepaid Assets for 7 years, with the latest figure at $4.6 million in Q2 2026.
- Prepaid Assets for Q2 2026 came in at $4.6 million, up 31.24% year-over-year; the trailing twelve-month figure through Jun 2026 was $4.6 million (up 31.24% YoY), and the FY2025 annual result was $3.9 million, up 53.69% from the prior year.
- Prepaid Assets improved to $4.6 million in Q2 2026, from $4.2 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $4.7 million in Q4 2022 and troughed at $2.3 million in Q2 2022.
- A 5-year average of $3.5 million and a median of $3.5 million in 2023 frame the typical range for Prepaid Assets.
- The widest annual swing landed in 2022, when Prepaid Assets surged 538.8%; it then sank 41.12% in 2023.
- A 5-year view of Prepaid Assets shows it stood at $4.7 million in 2022, then sank by 41.12% to $2.8 million in 2023, then slipped by 8.0% to $2.6 million in 2024, then surged by 53.69% to $3.9 million in 2025, then increased by 17.21% to $4.6 million in 2026.
- Per Business Quant data, the three most recent Prepaid Assets figures were $4.6 million in Q2 2026, $4.2 million in Q1 2026, and $3.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Design Therapeutics | 928.06 Mn | 720.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.62 Mn |
| Mar 31, 2026 | 2.40 Mn |
| Dec 31, 2025 | 3.94 Mn |
| Sep 30, 2025 | 1.68 Mn |
| Jun 30, 2025 | 2.17 Mn |
| Mar 31, 2025 | 3.97 Mn |
| Dec 31, 2024 | 1.30 Mn |
| Sep 30, 2024 | 3.17 Mn |
| Jun 30, 2024 | 2.43 Mn |
| Mar 31, 2024 | 3.20 Mn |
| Dec 31, 2023 | 2.79 Mn |
| Sep 30, 2023 | 3.60 Mn |
| Jun 30, 2023 | 1.96 Mn |
| Mar 31, 2023 | 2.57 Mn |
| Dec 31, 2022 | 4.73 Mn |
| Sep 30, 2022 | 4.26 Mn |
| Jun 30, 2022 | 2.35 Mn |
| Mar 31, 2022 | 112,000.00 |
| Dec 31, 2021 | 1.26 Mn |
| Sep 30, 2021 | 1.42 Mn |